Insider Selling: BeOne Medicines (NASDAQ:ONC) CEO Sells $933,589.80 in Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO John Oyler sold 3,410 shares of the stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $273.78, for a total transaction of $933,589.80. Following the completion of the sale, the chief executive officer owned 1,610 shares in the company, valued at approximately $440,785.80. This trade represents a 67.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

John Oyler also recently made the following trade(s):

• On Tuesday, June 16th, John Oyler sold 3,693 shares of BeOne Medicines stock. The stock was sold at an average price of $265.55, for a total transaction of $980,676.15.
• On Thursday, June 11th, John Oyler sold 1,949 shares of BeOne Medicines stock. The shares were sold at an average price of $257.24, for a total transaction of $501,360.76.
• On Monday, June 8th, John Oyler sold 4,940 shares of BeOne Medicines stock. The shares were sold at an average price of $270.56, for a total transaction of $1,336,566.40.

BeOne Medicines Trading Down 0.6%

BeOne Medicines stock traded down $1.78 during mid-day trading on Thursday, hitting $275.34. 231,751 shares of the company’s stock were exchanged, compared to its average volume of 260,107. The company’s 50 day simple moving average is $293.24 and its 200-day simple moving average is $310.76. The company has a quick ratio of 3.27, a current ratio of 3.64 and a debt-to-equity ratio of 0.20. The firm has a market capitalization of $30.21 billion, a P/E ratio of 61.60 and a beta of 0.49. BeOne Medicines Ltd. – Sponsored ADR has a fifty-two week low of $239.25 and a fifty-two week high of $385.22.

BeOne Medicines (NASDAQ:ONC) last posted its earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%.The firm had revenue of $1.51 billion during the quarter. On average, equities analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 earnings per share for the current year.

Institutional Investors Weigh In On BeOne Medicines

Hedge funds and other institutional investors have recently bought and sold shares of the company. EFG International AG bought a new position in shares of BeOne Medicines during the 4th quarter worth approximately $25,000. Leonteq Securities AG acquired a new position in BeOne Medicines during the fourth quarter worth $35,000. Daiwa Securities Group Inc. acquired a new position in BeOne Medicines during the second quarter worth $35,000. CWM LLC grew its position in BeOne Medicines by 32.8% in the fourth quarter. CWM LLC now owns 158 shares of the company’s stock valued at $48,000 after purchasing an additional 39 shares in the last quarter. Finally, Group One Trading LLC bought a new position in BeOne Medicines in the fourth quarter valued at $61,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of BeOne Medicines in a report on Monday, April 20th. Guggenheim upped their price target on shares of BeOne Medicines from $410.00 to $420.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Barclays increased their price objective on shares of BeOne Medicines from $405.00 to $409.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Wall Street Zen lowered shares of BeOne Medicines from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 20th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $413.00 price objective (up from $411.00) on shares of BeOne Medicines in a research report on Thursday, May 7th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $390.00.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.